# MetCool ACS- Metformin Cooling Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome

Study · id `cardio:ct-nct05305898` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05305898](<https://clinicaltrials.gov/study/NCT05305898>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05305898

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2000 participants.

## Technical summary

Registry record NCT05305898. Randomized; no masking; primary purpose other. Start 2022-02-08 (actual); primary completion 2025-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose other
- Phase: Phase 3
- Enrolled: 2000 participants (planned count; ClinicalTrials.gov record NCT05305898, source copy `cardio:ctgov-nct05305898-2022-03-31`, retrieved 2026-10-31)
- Started: 2022-02-08 (actual) (ClinicalTrials.gov record NCT05305898, source copy `cardio:ctgov-nct05305898-2022-03-31`, retrieved 2026-10-31)
- Primary completion: 2025-12 (anticipated) (ClinicalTrials.gov record NCT05305898, source copy `cardio:ctgov-nct05305898-2022-03-31`, retrieved 2026-10-31)
- Completion: 2025-12 (anticipated) (ClinicalTrials.gov record NCT05305898, source copy `cardio:ctgov-nct05305898-2022-03-31`, retrieved 2026-10-31)
- Countries: Poland (ClinicalTrials.gov record NCT05305898, source copy `cardio:ctgov-nct05305898-2022-03-31`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05305898-2022-03-31`, retrieved 2026-10-31)

## The registry's words

- Brief title: "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Metformin
- Lead sponsor: Military Institute od Medicine National Research Institute
- Lead sponsor class: OTHER
- Collaborator: ABM Industries
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)

## Provenance

Content hash: 719171bd1568e6388b51e8c9945a09b255b531c071df3c34b96c2c7579b7e756
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
